Thyroid Cancer Review 2: Management of Differentiated Thyroid Cancers

P. Nix; A. Nicolaides; A. P. Coatesworth


Int J Clin Pract. 2005;59(12):1459-1463. 

In This Article

Summary and Introduction

This is the second review article on thyroid cancer dealing with the common differentiated types that comprise 90% of thyroid cancers. Despite clinical management guidelines offered by a number of organisations including the British Association of Otolaryngologists and Head and Neck Surgeon, The British Thyroid Association, The American Association Of Endocrinologists, The American Thyroid Association and the National Cancer Centre Network, debate regarding the management of differentiated thyroid cancer continues. This is because of the absence of good quality research evidence as a consequence of the natural history of this disease.

This is the second of three review articles we have written on thyroid cancer. This paper deals with follicular and papillary thyroid cancer variants. Over 90% of thyroid cancers are of the follicular or papillary variants often termed differentiated thyroid cancer.[1] The initial detection and management of the differentiated cancers has evolved over the last few decades resulting in a 10-year cancer-specific mortality of less than 10%.[2] However, debate concerning initial treatment and follow-up of differentiated thyroid tumours still continues due to the paucity of prospective randomised trials. At present, management is based on large retrospective cohort studies.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.